Comgest Global Investors S.A.S. Purchases 92,800 Shares of Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Comgest Global Investors S.A.S. lifted its position in Johnson & Johnson (NYSE:JNJ) by 6.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,547,400 shares of the company’s stock after acquiring an additional 92,800 shares during the quarter. Johnson & Johnson accounts for 4.1% of Comgest Global Investors S.A.S.’s portfolio, making the stock its 11th largest position. Comgest Global Investors S.A.S. owned about 0.06% of Johnson & Johnson worth $200,203,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $25,000. Krane Funds Advisors LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $26,000. Financial Advantage Inc. purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $28,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares during the period. Finally, Eii Capital Management Inc. purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 72.22% of the company’s stock.

NYSE JNJ opened at $134.94 on Friday. The company’s 50-day simple moving average is $130.92 and its two-hundred day simple moving average is $133.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a market capitalization of $344.67 billion, a price-to-earnings ratio of 14.93, a price-to-earnings-growth ratio of 2.21 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The firm had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter in the previous year, the firm earned $2.05 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 8.66 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s payout ratio is currently 46.45%.

JNJ has been the topic of a number of research reports. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a research report on Friday, October 11th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Wells Fargo & Co cut their target price on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 16th. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Dividend Aristocrat Index

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Eastgroup Properties Inc  Expected to Post Quarterly Sales of $86.16 Million
Eastgroup Properties Inc Expected to Post Quarterly Sales of $86.16 Million
Escroco Emerald  Reaches 1-Day Trading Volume of $18.00
Escroco Emerald Reaches 1-Day Trading Volume of $18.00
Azart Hits 24-Hour Trading Volume of $2.00
Azart Hits 24-Hour Trading Volume of $2.00
InternationalCryptoX Market Capitalization Reaches $31,066.00
InternationalCryptoX Market Capitalization Reaches $31,066.00
StableUSD Price Down 0.2% This Week
StableUSD Price Down 0.2% This Week
Powell Industries, Inc.  Short Interest Update
Powell Industries, Inc. Short Interest Update


© 2006-2019 Ticker Report